Médecine

Paramédical

Autres domaines


S'abonner

Hypertrichotic patches as a mosaic manifestation of Proteus syndrome - 11/01/21

Doi : 10.1016/j.jaad.2020.01.078 
Deeti J. Pithadia, BS a, John W. Roman, MD a, Julie C. Sapp, ScM b, Leslie G. Biesecker, MD b, Thomas N. Darling, MD, PhD a,
a Department of Dermatology, Uniformed Services University, Bethesda, Maryland 
b National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 

Correspondence to: Thomas N. Darling, MD, PhD, Department of Dermatology, Uniformed Services University, 4301 Jones Bridge Rd, Bethesda, MD 20814.Department of DermatologyUniformed Services University4301 Jones Bridge RdBethesdaMD20814

Abstract

Background

Proteus syndrome is an overgrowth disorder caused by a mosaic activating AKT1 variant. Hair abnormalities in Proteus syndrome have rarely been reported, and frequencies of such findings have not been elucidated.

Objective

To define the types and frequencies of hair findings in individuals with Proteus syndrome.

Methods

A cross-sectional study was conducted of individuals with clinical features of Proteus syndrome and a confirmed pathogenic variant in AKT1 evaluated between November 1996 and June 2019 at the National Institutes of Health Clinical Center. Medical records were reviewed for patterning, density, and color of hair on the body and scalp.

Results

Of 45 individuals evaluated, 29 (64%) had asymmetric hypertrichosis on the body. This included unilateral blaschkoid hypertrichotic patches overlying normal skin or epidermal nevi in 16 (36%), unilateral nonblaschkoid hypertrichotic patches in 11 (24%), and unilateral limb hypertrichosis in 10 (22%). Diffuse, scattered, or patchy changes in scalp hair density or color were present in 11 individuals (24%).

Limitations

The retrospective, observational design, and limited longitudinal follow-up.

Conclusions

Asymmetric variations in hair distribution, thickness, length, and color contribute to the overall mosaic appearance of the skin in Proteus syndrome, an observation that provides novel insights into the role of phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) signaling in skin appendage development.

Le texte complet de cet article est disponible en PDF.

Key words : AKT, AKT1, Blaschko lines, hair, hair follicles, hypertrichosis, mosaicism, Proteus syndrome

Abbreviations used : AKT, PI3K


Plan


 Funding sources: This study was funded by the Intramural Research Program of the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH), grant HG-200388-04. This research was also made possible by the NIH Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and generous contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation, the American Association for Dental Research, the Colgate-Palmolive Company, Genentech, and other private donors. For a complete list, visit the Foundation website at www.fnih.org.
 Conflicts of interest: None disclosed.
 Portions of this work were presented at the 2019 Annual Southeastern Pediatric Research Conference, Atlanta, Georgia, June 10, 2019, and at the 44th Annual Meeting of the Society for Pediatric Dermatology, Austin, Texas, July 11-14, 2019.
 Disclaimer: The opinions and assertions expressed herein are those of the authors and do not reflect the official policy or position of the Uniformed Services University, the Department of Defense, or the National Institutes of Health.
 IRB approval status: Each study participant (or their parent, if a minor) provided written informed consent under the protocol 94-HG-0132, which was approved by the National Human Genome Research Institute (NHGRI) Institutional Review Board at the National Institutes of Health.
 Reprints not available from the authors.


© 2020  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 84 - N° 2

P. 415-424 - février 2021 Retour au numéro
Article précédent Article précédent
  • Mucocutaneous disease and related clinical characteristics in hospitalized children and adolescents with COVID-19 and multisystem inflammatory syndrome in children
  • Sergey Rekhtman, Rachel Tannenbaum, Andrew Strunk, Morgan Birabaharan, Shari Wright, Amit Garg
| Article suivant Article suivant
  • Thrombotic complications with interruption of direct oral anticoagulants in dermatologic surgery
  • Spyros M. Siscos, Brett C. Neill, Anjali Hocker Singh, Thomas L.H. Hocker

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.